Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...139140141142143144145146147148149...401402»
  • ||||||||||  AiRuiKa (camrelizumab) / Jiangsu Hengrui Pharma
    Journal:  Prognostic impact of sarcopenia in patients with hepatocellular carcinoma treated with PD-1 inhibitor. (Pubmed Central) -  Jan 6, 2023   
    This study included patients with HCC treated with camrelizumab between 1 March 2020 and 1 December 2021...HCC patients with sarcopenia tended to have higher levels of inflammation and lower levels of albumin than patients without sarcopenia. Sarcopenia is associated with a shorter PFS in HCC patients treated with PD-1 inhibitor.
  • ||||||||||  Review, Journal:  The influence of resistance training on adipokines in post-menopausal women: A brief review. (Pubmed Central) -  Jan 6, 2023   
    Additionally, the consistency of resistance training protocols as an intervention is not standardized or fully recognized. Therefore, the focus of this review is to establish a more comprehensive understanding of the benefits of resistance training on influencing adipokine levels based on changes to total body composition in postmenopausal women.
  • ||||||||||  Enrollment open, Surgery:  Bacterial Intestinal Gut Modification Around Cancer Surgery (BIG MACS) Diet (clinicaltrials.gov) -  Jan 6, 2023   
    P1,  N=24, Recruiting, 
    Information from CT scans, thus may help to better characterize these patients, and may be helpful in guiding therapeutic interventions. Not yet recruiting --> Recruiting
  • ||||||||||  Journal:  Ageing Skeletal Muscle: The Ubiquitous Muscle Stem Cell. (Pubmed Central) -  Jan 5, 2023   
    It is beyond the scope of this review to focus on ESCs, although their potential for enhancing our understanding of human development is huge (for a recent review see (Cyranoski Nature 555:428-430, 2018)). Rather, although ESCs and their epigenetic regulation will be introduced for background understanding, the focus will be on stem cells more generally, the role of epigenetics in stem cell fate, skeletal muscle, skeletal muscle stem cells, the impact of ageing on muscle wasting and the mechanisms underpinning loss, with a focus on epigenetic adaptation.
  • ||||||||||  Review, Journal:  Chronic Kidney Disease-induced Muscle Atrophy: Molecular Mechanisms and Promising Therapies. (Pubmed Central) -  Jan 4, 2023   
    This review not only discusses the mechanisms by which inflammation, oxidative stress, mitochondrial dysfunction promote CKD-induced muscle atrophy but also explores other CKD-related complications, such as metabolic acidosis, vitamin D deficiency, anorexia, and excess angiotensin II, as well as other related factors that play a role in CKD muscle atrophy, such as insulin resistance, hormones, hemodialysis, uremic toxins, intestinal flora imbalance, and miRNA. We highlight potential treatments and drugs that can effectively treat CKD-induced muscle atrophy in terms of complication treatment, nutritional supplementation, physical exercise, and drug intervention, thereby helping to improve the prognosis and quality of life of CKD patients.
  • ||||||||||  Review, Journal:  Male sex hormones, aging, and inflammation. (Pubmed Central) -  Jan 4, 2023   
    The exact mechanisms and impact of these changes in testosterone levels with age on health- and life-span are still not completely clear. Further research is needed to determine the optimal testosterone and androgen levels to protect from chronic age-related conditions such as frailty and osteoporosis.
  • ||||||||||  Dynamic anthropometrics: sarcopenia and survival in pancreatic cancer (SSO HUB Pan-Tumor Zone: CRS, HPB, Pan-Tumor & Upper GI) -  Jan 3, 2023 - Abstract #SSO2023SSO_180;    
    Repeated measurement of anthropometrics during NAT conveys valuable information regarding outcomes and potentially tumor biology of PDAC. This study suggests further investigation into the potential mechanisms of skeletal muscle loss, tumor-host interaction, and possible interventions to optimize body composition during NAT.
  • ||||||||||  Observational data, Journal:  Living alone reduces the decline of calf circumference among Chinese older adults: A 4-year longitudinal study. (Pubmed Central) -  Jan 3, 2023   
    This significant association was found in 65-79 years old (OR: 0.619, 95% CI: 0.407-0.942, p = 0.025), female (OR: 0.567, 95% CI: 0.408-0.790, p = 0.001) and city/town (OR: 0.461, 95% CI: 0.310-0.685, p < 0.001) subgroups but not in advanced age (≥80 years old), male and rural subgroups. This study revealed that living alone was associated with a decreased risk of calf circumference decline among older adults, and might be a protective factor for sarcopenia.
  • ||||||||||  Review, Journal:  Phase angle derived from bioelectrical impedance analysis as a marker for predicting sarcopenia. (Pubmed Central) -  Jan 3, 2023   
    Recently, phase angle (PhA), which is derived from bioelectrical impedance analysis (BIA), has received a great deal of attention, and numerous studies have been carried out to examine the relationship between PhA and sarcopenia in different conditions. Based on these studies, we expect that PhA could be used as a potential marker for sarcopenia in the future.
  • ||||||||||  Journal:  High prevalence of vertebral fractures at initiation of androgen deprivation therapy for prostate cancer. (Pubmed Central) -  Jan 3, 2023   
    Although the prevalence of osteoporosis, sarcopenia and 10-years fracture risk is low, there is a high prevalence of vertebral fractures in a third of the men with PCa at the time of ADT initiation. Besides a BMD measurement and fracture risk calculation using FRAX, a systematic vertebral fracture assessment should be considered in all men with PCa at initiation of ADT to provide a reliable baseline classification of VFs to improve identification of true incident VFs during ADT.
  • ||||||||||  Journal:  Therapeutic potential of mesenchymal stem cells and their derivatives in sarcopenia. (Pubmed Central) -  Jan 3, 2023   
    This article gives an overview of sarcopenia and the role of MSCs in skeletal muscle homeostasis. It also discusses the therapeutic potential of MSCs and their derivatives, as well as the underlying mechanisms of the therapeutic effects of MSCs and MSC-based products in sarcopenia.
  • ||||||||||  Review, Journal:  Fracture risk in obesity: a narrative review. (Pubmed Central) -  Jan 3, 2023   
    The specific characteristics of fractures risk associated with obesity should be considered by physicians in the diagnostic and therapeutic work-up of obese patients. This review outlines the current literature on this topic and aims to guide physicians regarding proper decisions to prevent fractures in patients with obesity.
  • ||||||||||  Journal, Metastases:  Does sarcopenia predict perioperative mortality in patients with advanced ovarian cancer? (Pubmed Central) -  Jan 3, 2023   
    According to the findings, patients had worse surgical outcomes and higher postoperative nonsurgical complication rate when sarcopenic patients were compared to nonsarcopenic patients. Moreover, postoperative mortality and length of hospital stay were significantly higher in sarcopenic patients in comparison to non-sarcopenic group.
  • ||||||||||  Review, Journal:  Nutrition and dietary supplements (Pubmed Central) -  Jan 3, 2023   
    At the end of life, care should primarily be focused on alleviating debilitating symptoms. To reliably support all patients affected by nutritional disorders, clear structures need to be established, responsibilities assigned and standardized procedures codified.
  • ||||||||||  Journal:  Dose-Dependent Association Between Sarcopenia and Moderate-to-Severe Thoracic Vertebral Fragility Fracture in Older Adults. (Pubmed Central) -  Jan 3, 2023   
    We further classified the participants into normal, sarcopenia, and severe sarcopenia and found that sarcopenia and severe sarcopenia had a dose-dependent association with prevalence of thoracic vertebral fragility fractures with OR of 2.56 (95% CI: 0.66-9.91) and 4.04 (95% CI: 1.24-13.20), respectively; P for trend = 0.014. Conclusion Sarcopenia is a potential risk factor for, and has a dose-dependent association with, moderate-to-severe thoracic fragility fracture in older adults at increased risk for fractures.
  • ||||||||||  Journal:  Risk Factors Affecting Muscle Mass Decline in Maintenance Hemodialysis Patients. (Pubmed Central) -  Dec 31, 2022   
    Further analysis found that dialysis vintage (β = 0.285, P = .030), 25(OH)D (β = -0.351, P = .007), and log NT-proBNP (β = 0.312, P = .020) were risk factors associated with the muscle mass decline rate in MHD patients. Age and serum 25(OH)D were associated with a higher risk of muscle mass decline, while 25(OH)D, dialysis vintage, and NT-proBNP were associated with the muscle mass decline rate in MHD patients.
  • ||||||||||  Retrospective data, Journal:  Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. (Pubmed Central) -  Dec 31, 2022   
    SGLT-2 inhibitors improve body composition in T2DM including body weight, body mass index, waist circumference, visceral fat area, subcutaneous fat area, percentage body fat and fat mass reduction, but cause adverse effects of reducing muscle mass. Therefore, until more evidence is obtained to support that SGLT-2 inhibitors increase the risk of sarcopenia, not only the benefit on body composition, but also the adverse effect of the reduction in muscle mass by SGLT-2 inhibitors in T2DM should be considered.
  • ||||||||||  Journal:  Markers for the Prediction of Probably Sarcopenia in Middle-Aged Individuals. (Pubmed Central) -  Dec 30, 2022   
    Among the markers that differed significantly were nitrates, and it was this that was associated with decreased muscle strength and appendicular mass, which may indicate both a possible mechanism and a possible predictive marker. The results of this study can be used to develop a screening method for diagnosing sarcopenia at the outpatient stage.
  • ||||||||||  Review, Journal:  What role do extracellular vesicles play in developing physical frailty and sarcopenia? : A systematic review. (Pubmed Central) -  Dec 30, 2022   
    Recent studies, although limited, depicted that EVs could be one of the underlying mechanisms of frailty and/or sarcopenia. There is a possibility that physical frailty and sarcopenia may have specific EV concentrations and cargo profiles; however, further research is required to fully understand the mechanisms and identify potential biomarkers and early preventative strategies for physical frailty and sarcopenia.